Trial | NCT00861016  Report issue

Title

Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate Hypertension
An Open-Label, Non-Comparative, Multi-Centre Study to Evaluate the Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet (Betaloc Zok) in Patients With Mild to Moderate Essential Hypertension

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    felodipine metoprolol ...

  • Study Participants

    310
This is an open-label, non-comparative, multi-centre clinical study to evaluate the Efficacy and safety of Metoprolol Succinate prolonged-release tablet (Betaloc Zok) in patients with mild to moderate essential hypertension.
Study Started
Oct 31
2005
Primary Completion
Apr 30
2006
Study Completion
May 31
2006
Last Update
Mar 13
2009
Estimate

Drug metoprolol succinate prolonged-release tablet and felodipine

a regimen that starts with metoprolol succinate prolonged-release tablet 47.5mg once daily, orally and allows for dose escalation to 95mg once daily, orally at 4 weeks if not controlled; at week 8 allows for the addition of felodipine sustained release tablet 5mg once daily, orally

  • Other names: Betaloc ZOK and Plendil

1 Experimental

The patients with mild to moderate essential hypertension

Criteria 

Inclusion Criteria:

Provision of written informed consent
Newly diagnosed essential hypertension who have not received anti- hypertensive treatment, or patients without antihypertensive medication in two weeks before screening, 90mmHg<SiDBP <110mmHg and SiSBP <180mmHg.

Exclusion Criteria:

Known or suspected secondary hypertension
Resting HR is < 55bpm.
Sick sinus syndrome
Atrioventricular block of first degree (with P-R>0.24seconds), or second or third degree
No Results Posted